Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.15
+0.08 (1.68%)
Oct 9, 2025, 11:52 AM EDT - Market open
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $1.99M in the quarter ending June 30, 2025, with 78.60% growth. This brings the company's revenue in the last twelve months to $8.10M, down -37.09% year-over-year. In the year 2024, Taysha Gene Therapies had annual revenue of $8.33M, down -46.07%.
Revenue (ttm)
$8.10M
Revenue Growth
-37.09%
P/S Ratio
172.45
Revenue / Employee
$110,932
Employees
73
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TSHA News
- 3 hours ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire
- 3 days ago - Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential - Seeking Alpha
- 5 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 7 days ago - Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - GlobeNewsWire